Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AVEO

AVEO Pharmaceuticals (AVEO) Stock Price, News & Analysis

AVEO Pharmaceuticals logo

About AVEO Pharmaceuticals Stock (NASDAQ:AVEO)

Advanced Chart

Key Stats

Today's Range
$14.99
$15.00
50-Day Range
$14.90
$15.00
52-Week Range
$3.06
$15.00
Volume
247,800 shs
Average Volume
601,442 shs
Market Capitalization
$521.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Receive AVEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVEO Stock News Headlines

New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Headlines

AVEO Stock Analysis - Frequently Asked Questions

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) posted its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. The biopharmaceutical company had revenue of $15.17 million for the quarter, compared to the consensus estimate of $14.29 million. AVEO Pharmaceuticals had a negative net margin of 30.79% and a negative trailing twelve-month return on equity of 81.66%.

Shares of AVEO Pharmaceuticals reverse split on Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that AVEO Pharmaceuticals investors own include Advanced Micro Devices (AMD), Micron Technology (MU), OPKO Health (OPK), Alibaba Group (BABA), Meta Platforms (META), Exelixis (EXEL) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/08/2021
Today
6/20/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AVEO
Employees
114
Year Founded
2001

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$53.34 million
Pretax Margin
-30.79%

Debt

Sales & Book Value

Annual Sales
$42.29 million
Price / Cash Flow
N/A
Book Value
$1.33 per share
Price / Book
11.28

Miscellaneous

Free Float
33,619,000
Market Cap
$521.45 million
Optionable
Optionable
Beta
1.00

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:AVEO) was last updated on 6/21/2025 by MarketBeat.com Staff
From Our Partners